This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's INVOKAMET, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKAMET XR, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKANA, containing active ingredient CANAGLIFLOZIN - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - BOEHRINGER INGELHEIM's GILOTRIF, containing active ingredient AFATINIB DIMALEATE - EISAI INC's DAYVIGO, containing active ingredient LEMBOREXANT - NOVARTIS PHARMACEUTICAL CORP's AFINITOR DISPERZ, containing active ingredient EVEROLIMUS - ASTRAZENECA PHARMACEUTICALS LP's KOSELUGO, containing active ingredient SELUMETINIB SULFATE Read More

This week, there are 7 drugs in the patent and exclusivity list. They are: - CUMBERLAND PHARMACEUTICALS INC's SANCUSO, containing active ingredient GRANISETRON - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - EPIZYME INC's TAZVERIK, containing active ingredient TAZEMETOSTAT HYDROBROMIDE - EVOFEM INC's SOLOSEC, containing active ingredient SECNIDAZOLE - ADVANCED ACCELERATOR APPLICATIONS USA INC's LUTATHERA, containing active ingredient LUTETIUM LU 177 DOTATATE Read More